Analysis snapshotSnapshot decision:REVIEW

BioFire FilmArray 2.0 Pair — Auction Analysis

Two BioFire FilmArray 2.0 instrument chassis are confirmed, but no control computer/software, peripherals, run evidence, readable serials, recall clearance, decontamination history, or service record is established. The bare-pair blind model supports a $0 hammer and remains REVIEW because no bid was captured.

Analysis snapshot · Historical — observed September 13, 2026. The scheduled close date of September 16, 2026 has passed. The price, evidence, economics, and recommendation remain exactly as recorded and are not current.

Decision at a glance

RecommendationREVIEW
Maximum hammer bid
$0

The auction bid ceiling supported by this analysis, if one is defensible; see costs below for buyer-premium treatment.

Why this decision

REVIEW: no high bid was captured, but the $1,100 bare-pair conservative resale leaves only the standard $500 profit at a zero hammer after stated reserves.

What to verify before bidding

  • FDA recall Z-3122-2024 remains open, but unreadable serials prevent classifying either auction unit as affected or unaffected.
  • No BioFire computer/software system, peripherals, successful run, or decontamination history is evidenced.
Review all risks and unknowns

See costs and maximum bid for the displayed assumptions and buyer-premium treatment.

Snapshot auction result
Not captured
Bidders
Not captured
Blind-model resale
$1,100
Snapshot provenance and timing · observed September 13, 2026 · scheduled close September 16, 2026

GSA Auctions sale 1-1-QSC-I-26-293, lot 059 · Oscar G. Johnson VA Medical Center, Iron Mountain, Michigan
Snapshot observed September 13, 2026
Scheduled close September 16, 2026
Analysis prepared September 13, 2026
Published September 13, 2026 · page updated September 13, 2026

Prepared and published by Oleksii Udod for LotCaliper.

View official GSA lot

Continue after this auction

This auction snapshot is historical. Continue with related research, or review a relevant published analysis whose recorded scheduled close has not passed.

These are individually prepared, time-stamped analyses with recorded scheduled closes. Verify the official auction before acting.

Auction snapshot

This page preserves the September 13, 2026 GSA observation for sale 1-1-QSC-I-26-293, lot 059. No high bid or bidder count was displayed; blank fields are not a $0 result or final no-bid outcome.

Two complete-looking molecular instruments can still be non-turnkey when their system computer, software, serial-specific recall clearance, decontamination history, and completed runs are unknown.

Review and correction history

Independent review not recorded for this legacy analysis. No corrections recorded.

View review and correction details

Independent review not recorded

Published before the current independent-review gate; no completed independent review is recorded.

How independent review works
How evidence is classified

Seller facts, photo-derived observations, manufacturer context, unknowns, and LotCaliper assumptions remain explicitly separated.

Source Confirmed

Seller-confirmed

  • Two BioFire Diagnostics FilmArray 2.0 instrument chassis are established.
  • Both housings, lids, pouch chambers, rear fans, Ethernet ports, and power inlets are visible.

Photo Derived

Photo-derived

  • The pair appears externally intact with opened pouch chambers present.
  • The photographs do not provide readable rear labels, a control computer, switch, software, or a completed test result.

Not Established

Not established

  • Exact catalog/serial labels, recall status, system computer/software, peripherals, pouch-loading station, cables, diagnostic history, successful runs, service, recall correction, and decontamination.

Manufacturer Context

Independent context

  • BioFire documents a one-to-eight-instrument system controlled by one computer running BioFire Software. U.S. FilmArray 2.0 sales ended in 2023 and reagent-utilization support is scheduled to end in January 2029.

Lotcaliper Assumption

LotCaliper assumptions

  • $1,100 conservative resale for two bare untested instrument chassis without computer/software or recall-clearance value.
  • $0 blind maximum hammer after selling friction, packing, test/decontamination effort, lifecycle/recall risk, and required profit.

Equipment identity

Laboratory · quantity 2

BioFire Diagnostics FilmArray 2.0 instruments; exact catalog and serial designation unresolved

Identity confidence: High

Identity evidence
  • Seller description and supplied photographs identify two BioFire Diagnostics FilmArray 2.0 units.

    GSA Auctions · Image · observed September 13, 2026

Configuration

BioFire system computer, preloaded BioFire Software, monitor, Ethernet switch, barcode reader, and connection hardware

Not established · no source evidence establishes presence or absence

Configuration evidence
  • The supplied photographs establish instrument chassis only; no computer/software system or normal peripherals are shown.

    GSA Auctions · Image · observed September 13, 2026

Pouch loading station, rack, power/Ethernet cables, reagent pouches, and service documentation

Not established · no source evidence establishes presence or absence

Configuration evidence
  • No complete matching workflow/accessory set, decontamination record, recall correction record, or service documentation is evidenced.

    GSA Auctions · Image · observed September 13, 2026

Exact catalog labels, serial numbers, and recall status for both units

Not established · no source evidence establishes presence or absence

Configuration evidence
  • Rear labels are too blurred to determine exact catalog designation or whether either serial appears in FDA recall Z-3122-2024.

    GSA Auctions · Image · observed September 13, 2026

Condition

Untested

No power-on, BioFire Software recognition, diagnostic pass, pouch run, thermocycling, sealing, imaging, or valid result is demonstrated.

Evidence confidence: High

Condition evidence
  • Intact housings and pouch chambers are not proof of a successful diagnostic run.

    GSA Auctions · Image · observed September 13, 2026

Market evidence

Market evidence strength

Medium Low

Public auditability

Limited Legacy

Evidence recency

Not Recorded

No structured comparable-evidence metadata was preserved for this dated snapshot. Public auditability is limited; the numeric resale snapshot cannot be independently audited from comparable records on this page.

Legacy evidence counts were not preserved. Unknown is not reported as zero.

Sensitivity and robustness

Requires Verification

The scenarios show potentially workable economics, but the stated verification gate must be resolved before bidding responsibly.

Bare instrument-pair blind model

Max hammer
$0
Gross resale model
$600–$1,500

The $0 ceiling credits two chassis only and does not assume control computer/software, recall clearance, service, warranty, or successful pouch runs.

Costs and maximum bid

Transaction / operating costAmountBasis
Selling Fees$165LotCaliper assumption: 15% of modeled gross resale.
Shipping$150LotCaliper pickup, packing, rigging, and inbound-logistics reserve; not a carrier or GSA quote.
Testing Repair Reserve$150LotCaliper functional-test and diagnostic reserve.
Risk Buffer$135No computer/software, recall, decontamination, platform-obsolescence, function, and specialist-liquidity risk reserve.
Buyer premium
Not modeled
Return requirements
$500 minimum profit · 30% minimum ROI
Computed bid constraints

Profit floor: $0

ROI floor: $284

Binding: Profit floor

Snapshot blind/as-is max hammer
$0
Modeled result at recorded bid
No bid recorded

This is a reseller ceiling, not a prediction of the auction's closing price. Any buyer premium or other unquoted acquisition charge must be deducted before bidding.

System completeness, recall status, and bare-instrument economics

The missing control environment is not a minor accessory issue: one compatible BioFire computer can control both instruments, but the chassis alone do not establish a usable system for a buyer without that environment.

FDA recall Z-3122-2024 is open and serial-specific. It does not mean both units are recalled, but the unreadable labels mean no recall-clearance credit can be used.

  • Obtain readable serials and verify each against the FDA recall record, including any completed recalibration documentation.
  • Confirm whether a BioFire computer/software system, switch, and peripherals are stored separately, then demonstrate software recognition and valid pouch runs for both units.

Recommendation and rationale

Snapshot decision

REVIEW

REVIEW: no high bid was captured, but the $1,100 bare-pair conservative resale leaves only the standard $500 profit at a zero hammer after stated reserves.

Confidence

Identity
High
Configuration
Low
Condition
Low
Market Support
Medium Low
Costs
Medium High

Market support assesses how well the available evidence supports the resale assumption. Exact third-party marketplace records may be omitted when source-use rights are unclear. Each dimension uses the published methodology rubric; a confidence label measures the strength and boundedness of its evidence, not the likelihood of a profitable outcome.

Risks and unknowns

High · Serial Specific Recall Unresolved

FDA recall Z-3122-2024 remains open, but unreadable serials prevent classifying either auction unit as affected or unaffected.

A recall is serial-specific and must not be generalized to every FilmArray 2.0 unit.

High · Control Workflow Not Established

No BioFire computer/software system, peripherals, successful run, or decontamination history is evidenced.

The instruments are designed to operate in a BioFire software-controlled system.

Sources

View cited public sources